Daniel Miles, MD
Hematology & Oncology · Fort Smith, ARNPI 1841648094
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,600, more than ten times the $14 reported in 2022. That places this record below the midpoint for hematology & oncology clinicians in AR, where the typical reported total is $4,667.
Across 121 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$353
- Daiichi Sankyo Inc.$346
- Pfizer$263
- Novartis$249
- GSK$152
- Merck$114
- plus $737 from 20 others
What the payments were for
- Food & beverage$2,18999%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $353 |
| Daiichi Sankyo Inc. | 14 | $346 |
| Pfizer | 19 | $263 |
| Novartis | 14 | $249 |
| GSK | 11 | $152 |
| Merck | 7 | $114 |
| Eisai Inc. | 6 | $113 |
| Tempus AI, Inc | 1 | $93 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| AbbVie | 4 | $74 |
| Sanofi | 2 | $44 |
| Stryker | 1 | $40 |
| Johnson & Johnson | 2 | $35 |
| Exelixis Inc. | 2 | $32 |
| Astellas Pharma US Inc | 2 | $32 |
| Array Biopharma Inc | 2 | $23 |
| Sobi, Inc | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Bayer | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Gilead | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Iovance Biotherapeutics, Inc. | 1 | $8 |
How this compares
$2,215 in reported general payments places this provider in the 40th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $218 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Fort Smith
- Isam Abdel-KarimFort Smith$199K
- Humdum DurraniFort Smith$54K
- Narender GorukantiFort Smith$20K
- Varant ArzoumanianFort Smith$7K
- Daniel MackeyFort Smith$6K
- Aswanth ReddyFort Smith$5K
- John WellsFort Smith$5K
- Suma Sri ChennapragadaFort Smith$2K
- Eric SchaeferFayetteville$466K
- Frits van RheeLittle Rock$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.